Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.

Biochimica et biophysica acta. Reviews on cancer - 1 Dec 2020

Lizardo Darleny Y, Kuang Chaoyuan, Hao Suisui, Yu Jian, Huang Yi, Zhang Lin

Abstract excerpt

Colorectal cancers (CRCs) with deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) often have sustained responses to immune checkpoint inhibitors (ICIs) including selective monoclonal antibodies against Program Death 1 (PD-1), Programmed Death Ligand 1(PD-L1), and cytotoxic T lymphocyte associated antigen 4 (CTLA-4). However, a substantial fraction of dMMR CRCs do not respond or ultimately...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Neoplasms
Share to Combined Modality Therapy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA Mismatch Repair

Share to Drug Therapy

Share to Gene Regulatory Networks

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Microsatellite Instability

Source

Open in PubMed Open full text

Identifiers

PMID: 33035640
DOI: 10.1016/j.bbcan.2020.188447
PMCID: PMC7886024

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.PMID 33035640Read ↗

Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?Semantic proximity Read ↗

Unraveling Resistance to Immunotherapy in MSI-High Colorectal CancerSemantic proximity Read ↗

Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.Semantic proximity Read ↗

The next bastion to be conquered in immunotherapy: microsatellite stable colorectal cancerSemantic proximity Read ↗

Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer LandscapeSemantic proximity Read ↗

Immunotherapy for the treatment of colorectal cancerSemantic proximity Read ↗

Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic Challenges.Semantic proximity Read ↗

Microsatellite Phenotype as a Guide for Immunotherapy in Colorectal Cancer: Current Status and Future Perspectives.Semantic proximity Read ↗

Oncological characteristics, treatments and prognostic outcomes in MMR-deficient colorectal cancerSemantic proximity Read ↗

A subset of patients with MSS/MSI‑low‑colorectal cancer showed increased CD8(+) TILs together with up‑regulated IFN‑γSemantic proximity Read ↗

Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal CancerSemantic proximity Read ↗

Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair DeficiencySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.